Nanomedicine Based Approaches For The Treatment Of Dementia

Nanomedicine-Based Approaches for the Treatment of Dementia explores a wide range of promising approaches for the diagnosis and treatment of dementia. The book begins with introductory sections on dementia and brain ailments that are followed by further chapters that discuss detailed information about challenges of drug delivery across the blood-brain barrier as well as the current status. This book helps readers design and develop novel drug delivery systems and devices for the treatment of dementia that take advantage of recent advances in nanomedical technologies. Numerous drug delivery systems have been developed recently for dementia. Unfortunately, most of them are ineffective since dementia is not a single disease. It is an umbrella term for several neurodegenerative conditions which alter brain functions. Due to this, there is an urgent need for innovative technologies/nano drug delivery systems to improve the targeting and delivery of therapeutic as well as diagnostic agents specifically for treating dementia. Explores promising approaches for the diagnosis and treatment of dementia Discusses advances in cutting-edge nanomedical technologies Focuses on the design, synthesis and application of nanocarriers in drug delivery

This book summarizes the latest research on drug and gene delivery to the central nervous system (CNS). The chapters address safety concerns regarding the nanotechnology that is needed to develop nanomedicine for clinical practice. Particular focus is given to new technologies that have emerged in recent years to deliver therapeutic materials, such as genes, drugs, and other agents using nanotechnologies of diverse origin. This is an ideal book for students, teachers, researchers, and clinicians interested in a deeper understanding of nanotechnological advances in therapeutic medicine. This book also: Broadens readers’ understanding of viral vector gene delivery to the brain for treating neurogenetic diseases as well as targeted gene delivery into the brain using microbubble-facilitated focused ultrasound Covers in detail the latest developments in delivering therapeutic materials, such as siRNA delivery to the brain for treating neurological diseases, neuroprotective effects of gelatin nanoparticles in stroke, and nanowired drug delivery for brain diseases, heat stroke, and CNS injury Enriches understanding of new technologies for delivering therapeutic materials treating Alzheimer’s Disease, including targeted nanodrug delivery through the blood-brain barrier and the superior neuroprotective effects of nanowired drug delivery in Alzheimer’s Disease

Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. Edited and written by leading experts in Alzheimer’s disease (AD) and other neurodegenerative disease drug development Describes existing drugs for AD and current molecular understanding of the condition Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets

Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes provides an overview of the important aspects of nanomedicine in order to illustrate how to design and develop novel and effective drug delivery systems using nanotechnology. The book is organized into three sections, beginning with an introduction to nanomedicine and its associated issues. Section two discusses the latest technologies in nanomedicine, while the third section covers future developments and challenges in the field. By focusing on the design, synthesis, and application of a variety of nanocarriers in drug and gene delivery, this book provides pharmaceutical and materials science students, professors, clinical researchers, and industry scientists with a valuable resource aimed at tackling the challenges of delivering drugs and genes in a more targeted manner. Explores a wide range of promising approaches for the diagnosis and treatment of diseases using the latest advances in cutting-edge nanomedical technologies Contains contributions from world-renowned experts and researchers working in the area of nanomedicine and drug delivery Covers the associated challenges and potential solutions to working with nanotechnology in drug delivery Highlights crucial topics, such as biopharmaceutical and toxicity issues, quality by design, drug targeting, and more

This book provides an overview of the current applications of nanomaterials in brain diseases, and introduces several novel nanomaterials that have excellent potential in this field. During the last two decades, nanotechnology had matured significantly as it has transitioned from a bench-top science to an applied technology. However, the application of nanomaterials in basic and clinical neuroscience is still at an early stage, and understanding how the intrinsic properties of nanomaterials translate to complex biological responses is an area of intensive research. Part 1 of the book focuses on the principles and strategies of nanomedicine in the brain diseases, while part 2 examines the applications of promising nanomaterials for therapy and diagnosis in the brain. Together they offer a comprehensive picture of advances in nanotechnology and their successful use in treating brain diseases in the past 20 years.

This book focuses on neurodegenerative diseases which have become a major threat to human health. Neurodegenerative diseases are age related disorders and have become increasingly prevalent in the elderly population in recent years. Hence, there is an urgent need to study and develop new strategies and alternative methods for the treatment of neurodegenerative diseases. This book showcases the promises that nanobiotechnology brings in research, diagnosis, and treatment of neurodegenerative diseases. It is very beneficial for varied group of readers including nanotechnologists, biotechnologists, pharmacists, medical professionals, bioengineers, biochemists and researchers working in this field. Nanobiotechnology in Neurodegenerative Diseases include various chapters including neurodegeneration and neurodegenerative diseases, nanotechnology for the rescue of neurodegenerative diseases, promising potential of nanomaterials for diagnosis and therapy of neurodegenerative diseases, nanotechnology mediated nose-to-brain drug delivery, and formulation and characterization of intranasal nanoparticles of antiretroviral drugs.

Among neurodegenerative diseases, those that lead to a state of dementia are the aim of several investigations. Dementia is a chronic disease the prevalence of which is increasing worldwide. The number of dementia patients in the world is approximately 50 million, and it is estimated that the number of patients will reach 131.5 million by 2050. This increase will be accompanied by a significant increase in medical expenditures and other expenses, especially for elderly patients. Therefore, the maintenance cost of dementia in the future is expected to be quite high. For this reason, several investigations aim, firstly, to describe the key mechanisms involved in the origin of dementia and, secondly, to establish preventive and therapeutic strategies in order to understand and mitigate this debilitating pathology. This volume of Frontiers in Clinical Drug Research - Dementia explores the current comorbidities that cause cognitive impairment and the current management alternatives for clinical cases of dementia. The reviews contributed in these volume will provide readers with a current perspective on the subject. The topics covered in this volume include: - Comorbidities inducing mild cognitive impairment - an evaluation of the risk caused by some pathological conditions - Tau-targeted therapy in Alzheimer's disease - history and current state - Emerging nanotherapeutic strategies in Alzheimer's disease - Implication of dehydroepiandrosterone on dementia related to oxidative stress - Polyphenol compounds as potential therapeutic agents in Alzheimer’s disease The volume is a timely update on dementia treatment for clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.

Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area. Written by international leaders in the field, the book assesses prospects for the emergence of effective agents and allows readers to better understand the challenges, failures, and future potential for research in Alzheimer’s disease. This book is a valuable resource to academic scientists carrying out translational research in Alzheimer’s disease, industrial scientists engaged in Alzheimer's drug discovery, executives in biopharmaceutical companies making strategic decisions regarding the direction of internal research and potential outside partnerships, and graduate-level students pursuing courses on Alzheimer's therapeutics. Provides a realistic but promising assessment of the potential of various therapeutic approaches to Alzheimer’s disease Focuses primarily on neuroprotective agents and cognitive enhancers, as well as approaches to targeting the amyloid B-peptide, tau and Apolipoprotein E Discusses alternative approaches, preclinical and clinical development issues, related biomarkers and diagnostics, and prevention and nonpharmacological approaches